Concert Pharmaceuticals, Inc. (NASDAQ:CNCE – Get Rating) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $5.29 and traded as high as $7.56. Concert Pharmaceuticals shares last traded at $7.40, with a volume of 663,240 shares trading hands.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 9th.
Concert Pharmaceuticals Trading Up 5.0 %
The stock has a market capitalization of $354.74 million, a price-to-earnings ratio of -2.31 and a beta of 0.30. The stock’s 50 day moving average is $5.29 and its 200 day moving average is $5.76.
Insiders Place Their Bets
In other Concert Pharmaceuticals news, CEO Roger D. Tung sold 9,240 shares of the firm’s stock in a transaction dated Friday, January 6th. The shares were sold at an average price of $7.24, for a total transaction of $66,897.60. Following the sale, the chief executive officer now directly owns 971,018 shares of the company’s stock, valued at approximately $7,030,170.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 11.33% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Concert Pharmaceuticals
Several hedge funds have recently modified their holdings of CNCE. International Biotechnology Trust PLC purchased a new position in shares of Concert Pharmaceuticals during the 2nd quarter worth about $620,000. Jane Street Group LLC purchased a new position in shares of Concert Pharmaceuticals during the 3rd quarter worth about $70,000. BNP Paribas Arbitrage SNC lifted its holdings in shares of Concert Pharmaceuticals by 9,436.2% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 11,062 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 10,946 shares during the period. UBS Group AG lifted its holdings in shares of Concert Pharmaceuticals by 42.6% during the 3rd quarter. UBS Group AG now owns 13,861 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 4,142 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Concert Pharmaceuticals during the 1st quarter worth about $47,000. 70.63% of the stock is owned by institutional investors and hedge funds.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders.
- Get a free copy of the StockNews.com research report on Concert Pharmaceuticals (CNCE)
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
- Tritium Is the Largest DC EV Charger Maker You’ve Never Heard Of
- Thor Industries Hammered Its Numbers. Is it a Buy?
- United Airlines Soars Ahead of Earnings…Time to Deplane?
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.